Qishenyiqi Dripping Pill for Coronary Microvascular Disease
ConditionCoronary Microvascular Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age40-75
SponsorQilu Hospital of Shandong University
About this trial
To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
Eligibility criteria
Qualifiers
Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
Coronary normal or stenosis < 20%;
Ischemic depression in ST segment during resting or exercise;
Blood flow reserve (CFR) of the anterior descending coronary artery < 2.0;
Disqualifiers
Previous myocardial infarction or PCI or CABG treatment;
A history of heart failure;
Severe arrhythmia;
Refractory hypertension or hypertension accompanied by left ventricular wall thickness > 12 mm;
Trial design
Treatments tested in this trial
- Qishenyiqi dripping pills 1 bag, three times a day
- Placebo 1 bag, three times a day
Treatment groups
162 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov